Tag: BurstDR
Abbott gains US FDA nod to treat non-surgical back pain with...
Abbott has announced that the US Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of chronic...
Abbott presents new data on streamlining patient-reported measures, BurstDR and more...
Abbott presented new data in more than 30 presentations and posters at the North American Neuromodulation Society (NANS) annual meeting (12–15 January 2023, Las...
Abbott launches “world’s smallest” implantable, rechargeable SCS system for chronic pain
Abbott has announced the US Food and Drug Administration (FDA) approval of the company's Eterna spinal cord stimulation (SCS) system, which it claims is...
CRISP study indicates clinical benefit of non-paraesthesia-based approaches in burst SCS...
The CRISP (Comparison of paraesthesia mapping to anatomic midline-based burst programming strategies) study, published in Neuromodulation: Technology at the Neural Interface, has found that...
Novel intermittent dosing burst spinal cord stimulation deemed safe and efficacious...
A novel intermittent dosing burst paradigm in spinal cord stimulation (SCS) has effectively relieved pain in patients with chronic intractable pain. Authors Timothy Deer,...
FDA approves low-dose spinal cord stimulator for chronic pain
Abbott has received FDA approval for its Proclaim XR recharge-free neurostimulation system for people with chronic pain. A press release reports that the Proclaim...
Similar success rates for anatomic and targeted lead placement for spinal...
“Anatomical lead placement is a viable alternative to targeted lead placement for spinal cord stimulation,” concluded Jason E Pope, Evolve Restorative Center, Santa Rosa,...
“A failure in SCS is not a failure of the therapy...
Defining true success as “being able to decrease or even eliminate a patient’s dependency on oral opioids”, Corey W Hunter, founder of Ainsworth Institute...
Positive data for BurstDR spinal cord stimulation
New results from a multicentre study of Abbott’s BurstDR stimulation show that lower-energy, intermittent doses of BurstDR stimulation—known as “microdosing”—can provide pain relief that is...
Majority of radiculopathy patients prefer burst to conventional tonic stimulation
BurstDR stimulation confers a greater reduction in leg and back pain intensity on patients with failed back surgery syndrome that tonic stimulation does, a...
Preliminary results of the CRISP study suggest that intraoperative paresthesia mapping...
The CRISP study is looking at patients with chronic back pain. They were implanted with two leads; one using paraesthesia mapping (PM) and the...
